Back to search

Article

Versican Proteolysis Predicts Immune Effector Infiltration and Post-Transplant Survival in Myeloma

2018-09-12

Abstract excerpt

<h4>ABSTRACT</h4> High-dose alkylator-based conditioning followed by autologous stem-cell transplantation (ASCT) is a therapeutic mainstay for eligible patients with multiple myeloma. However, post-transplant relapses are common and prognostic biomarkers are scarce. Relapses are characterized by the influx of regulatory myeloid cells and dysfunctional T effectors. We have shown that myeloma-infiltrating myeloid c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5688e81b-ae94-5d88-8b0d-d3e77ce8fa27
DOI
10.1101/415638
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Versican Proteolysis Predicts Immune Effector Infiltration and Post-Transplant Survival in MyelomaDOI 10.1101/415638
Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity
Elevated levels of Protein S in Multiple Myeloma bone marrow microenvironment regulate tumor progression and bone diseaseSemantic proximity
Single-cell transcriptomic analysis of NK cell dynamics in myeloma patients reveal persistent reduction of cytotoxic NK cells from diagnosis to relapseSemantic proximity
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple MyelomaSemantic proximity
Inflamed Natural Killer cells with adhesion defects are associated with a poor prognosis in Multiple MyelomaSemantic proximity
TPL2 kinase regulates the inflammatory milieu of the myeloma nicheSemantic proximity
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple MyelomaSemantic proximity
FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.Semantic proximity
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myelomaSemantic proximity
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatinsSemantic proximity
BCMA/CD19 dual-targeting with FasTCAR: AZD0120 demonstrates potent preclinical efficacy in multiple myelomaSemantic proximity
Select a neighboring publication to make it the new centre.